Joel Handler
Joel Handler
Yoga and hypertension [0.03%]
瑜伽与高血压
Debbie Cohen,Raymond R Townsend
Debbie Cohen
Barry J Materson
Barry J Materson
Hypertension and coronary artery disease: a summary of the American Heart Association scientific statement [0.03%]
高血压与冠状动脉疾病：美国心脏协会科学声明摘要
Clive Rosendorff
Clive Rosendorff
The American Heart Association scientific statement on the treatment of hypertension in the prevention and management of ischemic heart disease was published recently. The main recommendations were as follows: (1) For most adults with hyper...
Combination therapy with an angiotensin-converting enzyme inhibitor and a calcium channel blocker [0.03%]
血管紧张素转换酶抑制剂与钙通道阻滞剂的联合疗法
Brent M Egan
Brent M Egan
More than 1 medication is required in many hypertensive patients to reach blood pressure (BP) goals, and initial treatment with 2 agents has been recommended for patients whose BP level is >20/10 mm Hg above target. Diuretics reduce BP leve...
Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes [0.03%]
肥胖和非肥胖的糖尿病前期患者低水平白蛋白尿对脂联素的影响差异分析
Yuichiro Yano,Satoshi Hoshide,Joji Ishikawa et al.
Yuichiro Yano et al.
The goal of this study was to examine the association between adiponectin and low-grade albuminuria in nondiabetic persons and whether it differed between obese and nonobese individuals. Urinary albumin excretion (UAE) was assessed by overn...
Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension [0.03%]
低至中度高血压患者使用利尿剂或ACE抑制剂/ARB联合治疗出现醛固酮逃逸现象
Samira Ubaid-Girioli,Sílvia Elaine Ferreira-Melo,Leoní Adriana Souza et al.
Samira Ubaid-Girioli et al.
Renin-angiotensin-aldosterone system (RAAS) hyperactivity is implicated in the development of hypertension and progressive damage in target organs. Chronic inhibition of the RAAS or use of thiazide-type diuretics may trigger an aldoster-one...
Randomized Controlled Trial
Journal of clinical hypertension (Greenwich, Conn.). 2007 Oct;9(10):770-4. DOI:10.1111/j.1751-7176.2007.tb00091.x 2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study [0.03%]
达鲁森坦治疗难治性高血压患者的疗效和安全性：随机双盲安慰剂对照剂量范围研究结果
Henry R Black,George L Bakris,Michael A Weber et al.
Henry R Black et al.
In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant hypertension, receiving background therapy with >/=3 antihypertensive medications including a diuretic at full doses, wer...
A cost-effectiveness analysis of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy [0.03%]
糖尿病肾病中血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的疗效经济分析模型研究
Panagiotis C Stafylas,Pantelis A Sarafidis,Dimitrios M Grekas et al.
Panagiotis C Stafylas et al.
The aim of this study was to estimate the cost-effectiveness of renin-angiotensin-aldosterone system blockers in patients with diabetic nephropathy. A cost-effectiveness analysis was performed based on a meta-analysis of studies investigati...
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy [0.03%]
氯沙坦钾联合治疗未用氨氯地平单药有效控制血压的高血压患者及其与缬沙坦联合氨氯地平疗效的对比研究
Waymon Drummond,Mark A Munger,Mohammed Rafique Essop et al.
Waymon Drummond et al.
This study investigated the addition of the direct renin inhibitor aliskiren to amlodipine in patients with mild to moderate hypertension that was inadequately controlled with amlodipine alone. Following once-daily treatment with amlodipine...
Randomized Controlled Trial
Journal of clinical hypertension (Greenwich, Conn.). 2007 Oct;9(10):742-50. DOI:10.1111/j.1524-6175.2007.06614.x 2007